Arjo announces date for 2025 year-end report and conference call

Arjo will publish its 2025 year-end report on Friday, January 30 at 12:00 CET, followed by a conference call at 13:00 CET hosted by President & CEO Andréas Elgaard and CFO Christofer Carlsson for analysts, fund managers and media; verbal questions require prior registration and a recording will be available for three years. The release provides scheduling and investor-contact details (Maria Nilsson, EVP Communication; Erik Roslund, Investor Relations) but includes no financial figures or guidance in the announcement.

Analysis

Market structure: Arjo (ARJOB.ST) sits in defensive hospital equipment & patient-handling niches where aging demographics drive steady mid-single-digit organic demand but procurement is capex-sensitive. Winners are integrated-service providers (Arjo, Stryker SYK) that can squeeze pricing +100–200bps via consumables/service attach; losers are small OEMs and distributors exposed to hospital budget cuts. Higher bond yields compress hospital capex and increase financing costs, likely slowing large equipment replacements by 5–10% in stressed markets over 12–18 months.

Risk assessment: Immediate tail risk is an earnings/guide miss on Jan 30 (event in ~3 weeks) that can move the stock ±10–15% intraday; low-probability high-impact events include a major device recall or a significant reimbursement cut (>€50m-€100m hit). Short-term (weeks–months) hinge on order intake and FX: SEK moves >±3% vs EUR/USD will shift reported revenue by several percentage points; long-term (years) fundamentals remain supportive but vulnerable to distributor inventory cycles and public-health budgets.

Trade implications: Tactical pre-earnings exposure should be modest and volatility-aware: favor a 0.5–2% portfolio directional or options-sized trade rather than large outright positions. Consider long ARJOB.ST exposure if management signals margin recovery and order intake +5%+; hedge macro with shorter-dated puts or a call-spread to cap cost. Rotate modestly into healthcare-equipment (ARJOB.ST, SYK) and reduce exposure to capital-goods suppliers reliant on hospital capex.

Contrarian angles: Consensus may underweight services/consumables recurring revenue — if service attach rises 200–300bps, EBIT margins can surprise positively and drive a 15–25% re-rating over 6–12 months. The market often overreacts to one-quarter guidance misses; a disciplined buy-on-weakness rule (add if post-earnings drop >12% without structural guidance hit) can capture mean-reversion.

Key Decisions for Investors

• Establish a tactical 2% portfolio long in ARJOB.ST ahead of the Jan 30 report (initiate 7–14 days prior), size to pain-of-2% drawdown, set a stop-loss at -8% and trim into any +10% move within 4 weeks.
• If preferring options: buy a 1-month ATM call / sell a 1-month +15% call (call spread) on ARJOB.ST sized to 0.5–1% portfolio to capture upside while capping premium; enter 7–10 days pre-report and close within 3 trading days after the call to avoid second-weektime theta risk.
• Pair trade: go long ARJOB.ST and short GETI-B.ST (Getinge) 1:1 dollar-neutral, sized 1–2% net exposure, to express relative strength in patient-handling/services vs surgical-capex exposure; unwind if ARJO order intake misses by >10% Y/Y or Getinge reports margin expansion >150bps.
• Trigger-based risk cuts: reduce/exit ARJOB.ST exposure if (a) organic order intake down >10% Y/Y, (b) adjusted EBIT margin guidance misses consensus by >200bps, or (c) SEK moves >3% adverse vs EUR/USD within 30 days — monitor IR comments on distributor inventory levels during the Jan 30 call.